Search

Displaying results 1161 - 1170 of 7604 in total
  1. Drug

    Pheniramine

    go.drugbank.com/drugs/DB01620
    Approved

    Pheniramine's use as an anti-allergy medication has largely been supplanted by second-generation antihistamines such as [cetirizine] and [loratadine]. … Pheniramine is a first-generation antihistamine in the alkylamine class, similar to [brompheniramine] and [chlorpheniramine].

    Mixtures: Neo Citran Powder, Neo Citran A Powder
  2. Drug

    Galcanezumab

    go.drugbank.com/drugs/DB14042
    ApprovedInvestigational

    [A33112] Given this target specificity, lack of off-target toxicity, and characteristic proteolysis profile of immunoglobulin antibodies to not undergo metabolism by liver enzymes, galcanezumab possesses … Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP).

  3. Drug

    Hexaminolevulinate

    go.drugbank.com/drugs/DB06261
    ApprovedInvestigational

    Hexaminolevulinate is manufactured under the brand Cysview® by Photocure ASA. In Europe, Hexaminolevulinate is marketed under the brand Hexvix®. … invasive papillary cancer of the bladder for patients suspected or known to have lesion(s) on the basis of a prior cystoscopy.

  4. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). … [L11935] Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade.

  5. Drug

    Cenobamate

    go.drugbank.com/drugs/DB06119
    ApprovedInvestigational

    Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. … [L10653] Cenobamate was granted FDA approval on 21 November 2019.[L10653]

  6. Drug

    Certolizumab pegol

    go.drugbank.com/drugs/DB08904
    ApprovedInvestigational

    [A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819] … [A176606] Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be

  7. Drug

    Flucloxacillin

    go.drugbank.com/drugs/DB00301
    ApprovedInvestigationalWithdrawn

    Antibiotic analog of cloxacillin.

  8. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    [L35995] The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. … by Merck in 2019).

  9. Drug

    Sugemalimab

    go.drugbank.com/drugs/DB16641
    ApprovedInvestigational

    The antibody has also been granted the Breakthrough Therapy Designation by the FDA to treat relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) and an orphan drug designation … [L53333] In combination with platinum-based chemotherapy, sugemalimab is a first-line treatment indicated for adult populations with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR

  10. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    [A236035] This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury. … [L34615] It is the first and only FDA-approved treatment for this condition, which causes wood-like lesions to form on the mucous membranes of patients, providing an unmet medical need for patients with